Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences
February 25 2021 - 8:00AM
Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic
medicines company, announced today presentations at the following
virtual conferences:
- Cowen 41st Annual Health Care Conference
- Panel discussion: March 1 at 11:40 a.m. ET
- H.C. Wainwright Global Life Sciences Conference
- Fireside chat: Available on-demand March 9 at 7:00 a.m. ET
- CureMLD’s MLD Standards of Care Meeting
- Panel discussion, “Updates in MLD Clinical Therapies”: March 12
at 10:00 a.m. ET
- Oppenheimer & Co. 31st Annual Healthcare Conference
- Fireside chat: March 16 at 11:20 a.m. ET
The webcast presentations from the H.C. Wainwright and
Oppenheimer conferences will be accessible on Homology’s website in
the Investors section, and the webcast replays will be available on
the website for 90 days following the presentations.
About Homology Medicines, Inc.Homology
Medicines, Inc. is a clinical-stage genetic medicines company
dedicated to transforming the lives of patients suffering from rare
genetic diseases with significant unmet medical needs by curing the
underlying cause of the disease. Homology’s proprietary platform is
designed to utilize its human hematopoietic stem cell-derived
adeno-associated virus vectors (AAVHSCs) to precisely and
efficiently deliver genetic medicines in vivo either through a gene
therapy or nuclease-free gene editing modality across a broad range
of genetic disorders. Homology has a management team with a
successful track record of discovering, developing and
commercializing therapeutics with a particular focus on rare
diseases, and intellectual property covering its family of 15
AAVHSCs. Homology believes that its compelling preclinical data,
scientific expertise, product development strategy, manufacturing
capabilities and intellectual property position it as a leader in
the development of genetic medicines. For more information, please
visit www.homologymedicines.com.
Company Contacts Theresa McNeelyChief
Communications Officer and Patient Advocate
tmcneely@homologymedicines.com 781-301-7277
Media ContactMarisa CitranoCorporate
Communications
Associatemcitrano@homologymedicines.com617-335-2841
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Sep 2023 to Sep 2024